Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.
By C. Gridelli, F. Perrone, C. Gallo, S. Cigolari, A. Rossi, F. Piantedosi, S. Barbera, F. Ferraù, E. Piazza, F. Rosetti and 13 more. Journal of the National Cancer Institute, 2003
780 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/93511061b9384cbd3356654384977bd009e18f78
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- David H. Johnson
- D. Planchard
- K. Kerr
- C. Azzoli
- S. Novello
- E. Smit
- M. Hellmann
- C. Faivre-Finn
Citations in the corpus
- American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. (2004, background): “However, a larger, 3-arm trial with nearly 700 patients over the age of 70 —identified after the completion of our original literature search — concluded that the combination of vinorelbine gemcitabine did not provide a survival benefit over single-agent vinorelbine, or single-agent gemcitabine, and”
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, methodology): “Single-agent ChT with gemcitabine, vinorelbine, docetaxel [I, B] or pemetrexed (restricted to NSCC) [II, B] is an alternative treatment option [139, 140].”